Site Content

Aegea Biotechnologies, Inc. Announces the Issuance of Key Patents

  

Aegea Biotechnologies, Inc. Announces the Issuance of Key Patents 

Related to Its Core Next Generation Nucleic Acid Clinical Diagnostic Technologies

Aegea Biotechnologies, Inc. obtains multiple U.S. and International issued patents related to next generation nucleic acid technology including whole genome amplification, the specific capture of nucleic acid fragments of interest, and methods for the highly sensitive detection of genetic alterations of interest, including biomarkers associated with cancer.


SAN DIEGO, CALIFORNIA (October 10, 2018) Aegea Biotechnologies, Inc. (www.aegeabiotech.com), a biotechnology company focusing on the development and commercialization of next generation nucleic acid clinical diagnostic technologies, announces the issuance of a collection of patents including U.S. Patent 9,428,747 entitled METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS UTILIZING HAIRPIN LOOP OR DUPLEX PRIMERS, U.S. Patent 9,738,925 entitled METHODS FOR IMMOBILIZING TARGET NUCLEIC ACIDS UTILIZING COMBINATORIAL CAPTURE PROBES, and U.S. Patent 9,834,817 as well as Australian Patent 2012250516, Chinese patent 201280032293.0, and European Patent 2705162, all entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. These patents collectively enable the capture, amplification and precise detection of specific nucleic acid sequences of interest. 


U.S. Patent 9,834,817 and its Australian, Chinese, and European counterparts encompass the “switch-blocker” technology. When used with any sample types of interest, the switch-blocker technology provides ultra-high sensitivity and specificity for the detection of rare genetic alterations and may be used for the detection of mutations associated with cancer.

 

“We are very pleased by the issuance of this initial series of Aegea patents and expect many more patent allowances both in the U.S. and worldwide,” said Lyle Arnold, Ph.D., Aegea’s President and CEO. “Our goal is to leverage Aegea technology to advance biotechnology, particularly in the area of clinical diagnostics, and improve the lives of patients suffering from a wide variety of genetic and infectious diseases, as well as patients with cancer.” 


Michael Dunn, a board member at Aegea and acting Director of Business Development, added, "We are very excited about the issuance of these patents, in particular those covering the switch-blocker technology, which is the subject of a cross-license with a third party. Today, it is relatively straightforward to design new switch-blocker assays for mutations of interest, and to multiplex them.”


About Switch Blocker Technology

The switch-blocker technology is applicable to a broad range of molecular genomic platforms, including real-time polymerase chain reaction (qPCR), digital PCR, mass-spectroscopy, microarrays, capillary detection systems, Sanger sequencing, and Next Generation Sequencing (NGS). This technology allows robust amplification of genetic material harboring mutations or alterations by greatly enriching the number of desired target sequences and significantly reducing background noise by blocking amplification of normal (wild-type) genetic material. This combination significantly increases the detection sensitivity of mutations in low abundance. In addition, the cost of running assays to achieve high sensitivity, like NGS assays, can be reduced by two to three orders of magnitude, since the expense of sequencing large amounts of uninformative normal nucleic acid is eliminated.


About Aegea Biotechnologies

Aegea Biotechnologies, Inc. located in San Diego, California, is a biotechnology company focusing on the development and commercialization of next generation nucleic acid technologies. A primary focus for the company is nucleic acid technology innovations that embrace molecular diagnostic assays, qPCR technologies, and sequencing methods including both Sanger and NGS.


www.aegeabiotech.com

  

Investor Contact: 

Lyle Arnold, Ph.D.

larnold@aegeabiotech.com

(619) 851-8923


Business Contact:

Michael Dunn

mdunn@aegeabiotech.com


                                                                                               # # #